• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    2/14/24 9:00:56 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $SEER alert in real time by email
    SC 13G/A 1 tm246324d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    (Amendment No. 3)*

     

     

    SEER, INC.

    (Name of Issuer)

     

     

    Class A Common Stock, $0.00001 par value per share

    (Title of Class of Securities)

     

    81578P 106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 81578P 106   Page 2

                 
    1   

    NAME OF REPORTING PERSON:

     

    Omid Farokhzad

       

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)   ¨

    (b)   ¨

    3  

    SEC USE ONLY:

     

     

    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

     

    United States 

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

        5   

    SOLE VOTING POWER

     

    3,092,639(1)(2)

        6  

    SHARED VOTING POWER

     

    3,420,616 (2)(3)

        7  

    SOLE DISPOSITIVE POWER

     

    3,092,639 (1)(2)

        8  

    SHARED DISPOSITIVE POWER

     

    3,420,616 (2)(3)

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    6,513,255 (1)(2)(3) 

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):     ¨

     

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

    9.9 (2)(4)(5) 

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    IN

    (1)Consists of (i) 633,968 shares of Class A common stock and 134,579 shares of Class B common stock held of record by Omid Farokhzad (the “Reporting Person”); (ii) 2,163,092 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2023 and (iii) 161,000 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2023.
    (2)Each share of Class B common stock is convertible at any time into one share of Class A common stock.
    (3)Consists of (i) 1,303,478 shares of Class B common stock held of record by Dynamics Group LLC for which the Reporting Person serves as the sole member and (ii) 2,117,138 shares of Class B common stock held of record by SAF-BND Trust for which the Reporting Person’s spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the SAF-BND Trust.
    (4)Based on the quotient obtained by dividing (a) the aggregate amount beneficially owned by the Reporting Person as set forth in Row 9 by (b) the sum of (i) 59,780,244 shares of Class A common stock outstanding as of November 3, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 7, 2023 (the “Form 10-Q”); (ii) 3,555,195 shares of Class B common stock beneficially owned by the Reporting Person; (iii) 2,163,092 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2023 and (iv) 161,000 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2023. The aggregate number of shares of Class B common stock beneficially owned by the Reporting Person as set forth in clause “(a)” of this footnote are treated as converted into Class A common stock only for the purpose of computing the percentage ownership of the Reporting Person.
    (5)Each share of Class A common stock is entitled to one vote and each share of Class B common stock is entitled to ten votes. There were 4,044,969 shares of Class B common stock outstanding as of November 3, 2023, as reported in the Form 10-Q, including the 3,555,195 shares of Class B common stock beneficially owned by the Reporting Person as set forth in footnote “(4)” above. The percentage reported does not reflect the ten for one voting power of the Class B common stock because these shares are treated as converted into Class A common stock for the purpose of this report.

     

     

    Item 1

     

    (a)Name of Issuer:

     

    Seer, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices:

     

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

     

    Item 2

     

    (a)Name of Person Filing:

     

    Omid Farokhzad

     

    (b)Address or principal business office or, if none, residence:

     

    The address for the principal business office of Dr. Farokhzad is:

     

    c/o Seer, Inc.

    3800 Bridge Parkway, Suite 102

    Redwood City, California 94065

     

    (c)Citizenship:

     

    United States

     

    (d)Title and Class of Securities:

     

    Class A common stock, par value, $0.00001 per share.

     

    (e)CUSIP No.:

     

    81578P 106

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

     

    Item 4. Ownership

     

    (a)Amount beneficially owned: 6,513,255

     

    (b)Percent of class: 9.9

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to direct the vote: 3,092,639 (1)(2)

     

    (ii)Shared power to direct the vote: 3,420,616 (2)(3)

     

    (iii)Sole power to dispose or to direct the disposition of: 3,092,639 (1)(2)

     

    (iv)Shared power to dispose or to direct the disposition of: 3,420,616 (2)(3)

     

    (1)Consists of (i) 633,968 shares of Class A common stock and 134,579 shares of Class B common stock held of record by Omid Farokhzad (the “Reporting Person”); (ii) 2,163,092 shares of Class A common stock subject to options exercisable within 60 days of December 31, 2023 and (iii) 161,000 shares of Class A common stock issuable upon vesting of RSUs within 60 days of December 31, 2023.

     

    (2)Each share of Class B common stock is convertible at any time into one share of Class A common stock.

     

    (3)Consists of (i) 1,303,478 shares of Class B common stock held of record by Dynamics Group LLC for which the Reporting Person serves as the sole member and (ii) 2,117,138 shares of Class B common stock held of record by SAF-BND Trust for which the Reporting Person’s spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the SAF-BND Trust.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certifications

     

    Not applicable.

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

      /s/ Omid Farokhzad
      Omid Farokhzad

     

      
    Get the next $SEER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SEER

    DatePrice TargetRatingAnalyst
    7/5/2023$10.00Neutral
    JP Morgan
    1/4/2023$9.00 → $6.50Neutral → Underperform
    BofA Securities
    8/11/2022$20.00 → $12.00Overweight → Neutral
    JP Morgan
    3/1/2022$23.00 → $21.00Equal-Weight
    Morgan Stanley
    2/15/2022$46.00 → $23.00Equal-Weight
    Morgan Stanley
    10/15/2021Outperform
    Cowen
    8/13/2021$55.00 → $50.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SEER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Radoff-JEC Group Sends Open Letter to Seer, Inc. Unconflicted Independent Directors Meeta Gulyani and Nicolas Roelofs

    Raises Concerns About the Board's Continued Deference to Chair and CEO Dr. Omid Farokhzad in Light of His Track Record of Value Destruction Highlights Recently Filed Stockholder Lawsuit Against Seer and its Board Members, Which Alleges the Board Breached its Fiduciary Duties in Connection with the Adoption of the NOL Poison Pill Calls on the Board to Immediately Announce a Sale Process to Avoid Further Value Destruction Under Dr. Farokhzad Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding common stock of Seer, Inc. (NASDAQ:SEER), today issued the following open letter to i

    3/4/26 8:00:00 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    SEC Filings

    View All

    Amendment: SEC Form 8-A12B/A filed by Seer Inc.

    8-A12B/A - Seer, Inc. (0001726445) (Filer)

    3/16/26 8:55:17 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - Seer, Inc. (0001726445) (Filer)

    3/16/26 8:41:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SCHEDULE 13D/A filed by Seer Inc.

    SCHEDULE 13D/A - Seer, Inc. (0001726445) (Subject)

    3/2/26 5:19:01 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CFO Horn David R. sold $15,447 worth of shares (7,743 units at $1.99), decreasing direct ownership by 2% to 501,262 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/19/26 4:11:51 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    CEO AND CHAIR Farokhzad Omid sold $48,646 worth of shares (24,385 units at $1.99), decreasing direct ownership by 0.72% to 3,349,064 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/19/26 4:06:45 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CFO Horn David R. was granted 79,000 shares, increasing direct ownership by 18% to 509,005 units (SEC Form 4)

    4 - Seer, Inc. (0001726445) (Issuer)

    2/5/26 6:54:29 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    JP Morgan resumed coverage on Seer with a new price target

    JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00

    7/5/23 7:25:16 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by BofA Securities with a new price target

    BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously

    1/4/23 9:03:59 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer downgraded by JP Morgan with a new price target

    JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously

    8/11/22 6:17:02 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Financials

    Live finance-specific insights

    View All

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th

    2/5/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Leadership Updates

    Live Leadership Updates

    View All

    Seer Appoints Isaac Ro to its Board of Directors

    REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. "We are excited to welcome Isaac to our board," said Omid Farokhzad, Chair and CEO of Seer. "Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven track record of guiding companies through transformative growth will be invaluable as we continue to execute on key milestones and accelerate the impact of our platform." "I'm looking forward to work

    9/2/25 7:00:00 AM ET
    $SEER
    $WGS
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Retail: Computer Software & Peripheral Equipment
    Technology

    Seer Appoints Nicolas Roelofs to its Board of Directors

    REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life

    8/14/24 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Announces Appointment of Scott D. Thomas as Chief Commercial Officer

    REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented

    3/16/22 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $SEER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    8/2/24 6:33:25 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Seer Inc.

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    7/8/24 4:32:39 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Seer Inc. (Amendment)

    SC 13G/A - Seer, Inc. (0001726445) (Subject)

    4/10/24 10:06:09 AM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials